ME01534B - 17-HIDROKSI-17-PENTAFLUORETIL-ESTRA-4,9(10)-DIEN -11-ARIL-DERIVAT, POSTUPAK NJEGOVE PROIZVODNJE l NJEGOVA UPOTREBA U TERAPIJI BOLESTI - Google Patents

17-HIDROKSI-17-PENTAFLUORETIL-ESTRA-4,9(10)-DIEN -11-ARIL-DERIVAT, POSTUPAK NJEGOVE PROIZVODNJE l NJEGOVA UPOTREBA U TERAPIJI BOLESTI

Info

Publication number
ME01534B
ME01534B MEP-2013-69A MEP6913A ME01534B ME 01534 B ME01534 B ME 01534B ME P6913 A MEP6913 A ME P6913A ME 01534 B ME01534 B ME 01534B
Authority
ME
Montenegro
Prior art keywords
hydroxy
production
pentafluorethyl
estra
dien
Prior art date
Application number
MEP-2013-69A
Other languages
English (en)
Inventor
Wolfgang Schwede
Ulrich Klar
Carsten Möller
Andrea Rotgeri
Wilhelm Bone
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43383964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME01534(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of ME01534B publication Critical patent/ME01534B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pronalazak se odnosi na jedinjenje 17-hidroksi-17-pentafluoretil-estra-4,9(10)-dien-11-aril-derivat formule I sa antagonističkim efektom na progesteron i na procese za njegovu proizvodnju, njegovo korišćenje za lečenje i/ili profilaksu oboljenja, njegovu upotrebu u proizvodnji lekova za lečenje i/ili profilaksu oboljenja, posebno fibroida materice (miomi, leiomiomi materice), endometrioze, teških menstrualnih krvarenja, meningioma, hormonskih karcinoma dojke i simptoma povezanih sa menopauzom ili za kontrolu rađanja i hitne kontracepcije.
MEP-2013-69A 2009-07-20 2010-07-07 17-HIDROKSI-17-PENTAFLUORETIL-ESTRA-4,9(10)-DIEN -11-ARIL-DERIVAT, POSTUPAK NJEGOVE PROIZVODNJE l NJEGOVA UPOTREBA U TERAPIJI BOLESTI ME01534B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009034362A DE102009034362A1 (de) 2009-07-20 2009-07-20 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
EP10735198A EP2432798B1 (de) 2009-07-20 2010-07-07 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivat, verfahren zu seine herstellung und seine verwendung zur behandlung von krankheiten
PCT/EP2010/004149 WO2011009531A2 (de) 2009-07-20 2010-07-07 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten

Publications (1)

Publication Number Publication Date
ME01534B true ME01534B (me) 2014-04-20

Family

ID=43383964

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2019-131A ME03400B (me) 2009-07-20 2010-07-07 (11beta, 17beta)-17-hdroksi-11-[4-(metilsulfonil)fenil]-17- (pentalfuorometil)estra-4,9-dien-3-on za upotrebu za lečenje bolesti
MEP-2013-69A ME01534B (me) 2009-07-20 2010-07-07 17-HIDROKSI-17-PENTAFLUORETIL-ESTRA-4,9(10)-DIEN -11-ARIL-DERIVAT, POSTUPAK NJEGOVE PROIZVODNJE l NJEGOVA UPOTREBA U TERAPIJI BOLESTI

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2019-131A ME03400B (me) 2009-07-20 2010-07-07 (11beta, 17beta)-17-hdroksi-11-[4-(metilsulfonil)fenil]-17- (pentalfuorometil)estra-4,9-dien-3-on za upotrebu za lečenje bolesti

Country Status (48)

Country Link
US (4) US20120149670A1 (me)
EP (4) EP2623510B1 (me)
JP (3) JP5795312B2 (me)
KR (2) KR101687853B1 (me)
CN (1) CN102482317B (me)
AR (1) AR077491A1 (me)
AU (1) AU2010275849B2 (me)
BR (1) BR112012001344B8 (me)
CA (1) CA2768407C (me)
CL (1) CL2012000166A1 (me)
CO (1) CO6491067A2 (me)
CR (2) CR20170091A (me)
CU (1) CU20120012A7 (me)
CY (3) CY1114260T1 (me)
DE (1) DE102009034362A1 (me)
DK (3) DK2623510T3 (me)
DO (2) DOP2012000015A (me)
EA (2) EA025150B1 (me)
EC (2) ECSP12011616A (me)
ES (3) ES2648292T3 (me)
GT (1) GT201200012A (me)
HK (1) HK1171456A1 (me)
HN (1) HN2012000137A (me)
HR (3) HRP20130558T1 (me)
HU (2) HUE043757T2 (me)
IL (1) IL216967B (me)
IN (1) IN2012DN00598A (me)
JO (2) JO3009B1 (me)
LT (2) LT3252069T (me)
MA (1) MA33445B1 (me)
ME (2) ME03400B (me)
MX (2) MX2012000930A (me)
MY (1) MY179447A (me)
NO (1) NO2623510T3 (me)
NZ (2) NZ623417A (me)
PE (2) PE20121085A1 (me)
PL (3) PL2432798T3 (me)
PT (3) PT2432798E (me)
RS (1) RS52811B (me)
SG (3) SG10201404159VA (me)
SI (3) SI2432798T1 (me)
TN (1) TN2012000028A1 (me)
TR (1) TR201908600T4 (me)
TW (1) TWI505830B (me)
UA (1) UA106502C2 (me)
UY (1) UY32791A (me)
WO (1) WO2011009531A2 (me)
ZA (1) ZA201201222B (me)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102011088270A1 (de) 2011-12-12 2013-06-13 Bayer Intellectual Property Gmbh (11ß ,17ß)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on zur Behandlung von Morbus Charcot Marie Toot
PT2983671T (pt) * 2013-04-11 2019-02-25 Bayer Pharma AG Forma farmacêutica de antagonista de recetor de progesterona
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
MA46298A (fr) * 2015-05-18 2019-07-31 Bayer Pharma AG Modulateur sélectif du récepteur de la progestérone (sprm) pour son utilisation dans le traitement des saignements menstruels abondants
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
EP3384913A1 (en) * 2017-04-03 2018-10-10 Bayer Pharma Aktiengesellschaft Selective progesterone receptor modulators and stabilized estrogen level in patient
WO2019080811A1 (zh) 2017-10-26 2019-05-02 苏州科睿思制药有限公司 一种选择性孕酮受体调节剂的晶型及其制备方法
WO2023167878A1 (en) 2022-03-01 2023-09-07 Altin Biosciences Corporation Crila® and egcg compositions for treatment of fibroids

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5272140A (en) 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
FR2620707B1 (fr) 1987-09-18 1989-12-08 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique a 3, 4 ou 6 chainons en position 17, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FR2644789B1 (fr) 1989-03-22 1995-02-03 Roussel Uclaf Nouveaux steroides 19-nor, 3-ceto comportant une chaine en 17 aminosubstituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
ES2127181T3 (es) 1989-08-04 1999-04-16 Schering Ag 11-beta-aril-gona-4,9-dien-3-onas.
US5407928A (en) 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
CA2100514C (en) * 1992-07-29 2005-03-29 Johannes A. M. Hamersma 17-spiromethylene steroids
FR2718354B1 (fr) 1994-04-08 1996-05-03 Roussel Uclaf Application des composés antiglucocorticoïde pour la préparation de médicaments destinés à la prévention ou au traitement des manifestations liées au syndrome de sevrage des narcotiques et les compositions les renfermant.
DE4426601A1 (de) 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
EP1488794A3 (en) 1994-11-22 2005-04-20 Balance Pharmaceuticals, Inc. Methods of contraception
WO1997041145A1 (en) 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
WO1998005679A2 (en) 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
FR2757400B1 (fr) 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US20010016578A1 (en) 1997-06-18 2001-08-23 Balance Pharmaceuticals, Inc. Compositions and methods for contraception and for treatment of benign gynecological disorders
JPH11171774A (ja) 1997-12-05 1999-06-29 Kyowa Hakko Kogyo Co Ltd 血球増多剤
AR015500A1 (es) 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
AU3344099A (en) 1998-04-17 1999-11-08 Kyowa Hakko Kogyo Co. Ltd. Analgetic agent
US6172052B1 (en) * 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6476079B1 (en) 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
EP1157996A1 (de) 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
AU2002218179B2 (en) 2000-09-18 2006-11-16 Merck Serono Sa Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op)
DE10051609A1 (de) 2000-10-18 2002-05-02 Schering Ag Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
ES2253443T3 (es) 2000-10-18 2006-06-01 Schering Aktiengesellschaft Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.
WO2002032429A2 (en) 2000-10-18 2002-04-25 Schering Aktiengesellschaft Use of inhibitors of progesterone receptor for treating cancer
CN1244329C (zh) * 2001-01-09 2006-03-08 舍林股份公司 抗促孕素在制备用于抑制雌性哺乳动物中发生子宫内膜加速成熟的药物中的应用
US20020143000A1 (en) * 2001-01-09 2002-10-03 Christa Hegele-Hartung Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
ATE307823T1 (de) 2002-05-03 2005-11-15 Schering Ag 17a-fluoralkyl-11beta-benzaldoxim-steroide, verfahren zu deren herstellung, diese steroide enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
DE10221034A1 (de) 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
PT1768625E (pt) 2004-07-09 2011-04-18 Hra Pharma Lab Composições de libertação sustida contendo moduladores do receptor da progesterona
TW200639154A (en) 2005-03-18 2006-11-16 Hirose Engineering Co Ltd Nile red type red light emitting compound and light emitting device
US20070105828A1 (en) 2005-08-19 2007-05-10 Glenmark Pharmaceuticals Limited Novel polymorph form M of mifepristone and process for its preparation
EP1862468A1 (de) 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
US20090075989A1 (en) * 2006-12-21 2009-03-19 Wolfgang Schwede Non-steroidal progesterone receptor modulators
KR101153530B1 (ko) 2007-03-01 2012-06-12 피알에스 메디터레이니언 리미티드 자외선 저항성의 다층 셀룰러 제한 시스템
EP2123279A1 (de) 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten

Also Published As

Publication number Publication date
NZ623417A (en) 2015-10-30
JP6130087B1 (ja) 2017-05-17
MX2012000930A (es) 2012-03-26
US8278469B2 (en) 2012-10-02
EP3252069A1 (de) 2017-12-06
CU20120012A7 (es) 2012-07-31
CR20170091A (es) 2018-02-06
PE20170084A1 (es) 2017-03-30
JP2012533575A (ja) 2012-12-27
RS52811B (en) 2013-10-31
TW201105331A (en) 2011-02-16
ME03400B (me) 2020-01-20
HK1171456A1 (en) 2013-03-28
MY179447A (en) 2020-11-06
BR112012001344B8 (pt) 2021-05-25
SG10201404159VA (en) 2014-10-30
SI3252069T1 (sl) 2019-06-28
DOP2012000015A (es) 2016-04-15
CU24080B1 (me) 2015-03-30
IL216967B (en) 2018-06-28
DOP2015000276A (es) 2018-04-15
SG10201811830PA (en) 2019-02-27
KR101687853B1 (ko) 2016-12-19
AR077491A1 (es) 2011-08-31
HRP20171805T1 (hr) 2017-12-29
SI2623510T1 (sl) 2017-12-29
CA2768407C (en) 2017-10-24
EA201301263A1 (ru) 2014-08-29
US20120149670A1 (en) 2012-06-14
ES2730209T3 (es) 2019-11-08
CY1119661T1 (el) 2018-04-04
US20150342962A1 (en) 2015-12-03
CR20120040A (es) 2012-03-12
TN2012000028A1 (en) 2013-09-19
EA201200121A1 (ru) 2012-07-30
NO2623510T3 (me) 2018-01-20
UA106502C2 (uk) 2014-09-10
EP2623510B1 (de) 2017-08-23
WO2011009531A2 (de) 2011-01-27
EP2623510A1 (de) 2013-08-07
SG177519A1 (en) 2012-02-28
DE102009034362A1 (de) 2011-01-27
CN102482317B (zh) 2014-09-17
TR201908600T4 (tr) 2019-07-22
IL216967A0 (en) 2012-02-29
US20120094969A1 (en) 2012-04-19
DK2432798T3 (da) 2013-07-01
HRP20191049T1 (hr) 2019-09-20
MX338217B (es) 2016-04-07
EA025150B1 (ru) 2016-11-30
EA021946B1 (ru) 2015-10-30
CA2768407A1 (en) 2011-01-27
LT2623510T (lt) 2017-12-11
TWI505830B (zh) 2015-11-01
ZA201201222B (en) 2022-11-30
HUE043757T2 (hu) 2019-09-30
EP3272763A1 (de) 2018-01-24
ECSP18047708A (es) 2018-06-30
AU2010275849A1 (en) 2012-02-02
JP2017105813A (ja) 2017-06-15
BR112012001344B1 (pt) 2020-09-24
PL3252069T3 (pl) 2019-09-30
US10155004B2 (en) 2018-12-18
PL2623510T3 (pl) 2018-02-28
PE20121085A1 (es) 2012-08-04
WO2011009531A3 (de) 2011-04-28
UY32791A (es) 2011-02-28
KR101854059B1 (ko) 2018-05-02
PT2623510T (pt) 2017-11-24
GT201200012A (es) 2013-10-15
JO3009B1 (ar) 2016-09-05
CY1114260T1 (el) 2016-08-31
SI2432798T1 (sl) 2013-08-30
CY1121926T1 (el) 2020-10-14
EP3252069B1 (de) 2019-04-03
KR20120046182A (ko) 2012-05-09
HRP20130558T1 (hr) 2013-07-31
DK3252069T3 (da) 2019-06-24
MA33445B1 (fr) 2012-07-03
PL2432798T3 (pl) 2013-08-30
BR112012001344A2 (pt) 2016-03-15
HN2012000137A (es) 2015-05-04
PT2432798E (pt) 2013-06-28
KR20160093110A (ko) 2016-08-05
ES2648292T3 (es) 2017-12-29
EP2432798B1 (de) 2013-04-03
PT3252069T (pt) 2019-06-18
CO6491067A2 (es) 2012-07-31
NZ597639A (en) 2014-04-30
US20170202857A1 (en) 2017-07-20
DK2623510T3 (en) 2017-12-04
CL2012000166A1 (es) 2012-08-31
CN102482317A (zh) 2012-05-30
ES2416461T3 (es) 2013-08-01
JP2015178522A (ja) 2015-10-08
AU2010275849B2 (en) 2014-12-18
HUE037339T2 (hu) 2018-08-28
JP5795312B2 (ja) 2015-10-14
IN2012DN00598A (me) 2015-06-12
EP2432798A2 (de) 2012-03-28
LT3252069T (lt) 2019-06-10
US9717739B2 (en) 2017-08-01
JO3732B1 (ar) 2021-01-31
ECSP12011616A (es) 2012-02-29

Similar Documents

Publication Publication Date Title
ME01534B (me) 17-HIDROKSI-17-PENTAFLUORETIL-ESTRA-4,9(10)-DIEN -11-ARIL-DERIVAT, POSTUPAK NJEGOVE PROIZVODNJE l NJEGOVA UPOTREBA U TERAPIJI BOLESTI
WO2011009529A3 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten
WO2011009530A3 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9 (10)-dien-11-acyloxyalkylenphenyl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten
UA115558C2 (uk) Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань
WO2011009534A3 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten
WO2011098437A3 (de) Progesteronrezeptorantagonisten
TN2015000362A1 (en) Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (akr1 c3)
BR112012002265B8 (pt) composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
CL2010001528A1 (es) Compuestos derivados del acido 7-fenoxicroman-4-carboxilico sustituido; proceso de preparacion; compuesto intermediario; composicion farmaceutica de dicho compuesto; y su uso como antagonista de los receptores de prostaglandina d2 (pgd2) para tratar trastornos inmunologicos, enfermedades alergicas, trastornos inflamatorios.
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
BR112012023281A2 (pt) composto ou sal do mesmo, composição farmacêutica, métodos para produzir efeito antiprogestacional em paciente e para tratar condição dependente de progesterona e usos de composto ou sal do mesmo farmaceuticamente aceitável do mesmo e de composição
BR112015025706A2 (pt) forma de dosagem do antagonista do receptor de progesterona
WO2010104691A3 (en) Estrogenic compounds and their methods of use
MY179215A (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease
NZ622081A (en) Estra-1,3,5
CU20100181A7 (es) Derivados de (pirazolilcarbonil)imidazolidinonas para el tratamiento de enfermedades retrovirales